The Department of Justice has provided further guidance on what they will be looking for in assessing corporate compliance programs. The latest guidance focuses on three “fundamental questions” that the Government will...more
Rochester Drug Co-Operative, Inc. (“RDC”), one of the 10 largest pharmaceutical distributors in the United States, was recently charged along with its former Chief Executive Officer and former Chief Compliance Officer, for...more
5/28/2019
/ CCO ,
CEOs ,
Compliance ,
Controlled Substances ,
Controlled Substances Act ,
Corporate Executives ,
Criminal Conspiracy ,
Criminal Investigations ,
DEA ,
Deferred Prosecution Agreements ,
Drug Distribution ,
New Guidance ,
Opioid ,
Personal Liability ,
Pharmaceutical Industry ,
Pharmacies ,
Unlawful Distribution
The United States Department of Justice (DOJ) has issued new guidelines regarding cooperation and credit for self-disclosure specifically in False Claims Act matters. Such guidelines provide an overview of factors to be...more
5/20/2019
/ Best Practices ,
Cooperation ,
Corporate Liability ,
Corporate Misconduct ,
Department of Justice (DOJ) ,
False Claims Act (FCA) ,
Federal Contractors ,
Government Investigations ,
Internal Investigations ,
New Guidance ,
Personal Liability ,
Remedial Actions ,
Self-Disclosure Requirements ,
Subsequent Remedial Measures ,
Voluntary Disclosure Agreement